AR and prostate carcinoma: A 6-d-long treatment with IRC117539 dramatically reduced the survival of cultured LNCaP, VCaP, and 22Rv1 prostate cancer cell lines whose proliferation was previously reported to be AR-driven (Fig 1A and B).